TNFRSF17 and myasthenia gravis: Both types of cells express the B‐cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRS17), making it a compelling target for the treatment of many antibody‐mediated diseases, including MG [7].